Hero MotoCorp’s March quarter showed strong year-on-year growth, but sequential performance was impacted by rising input costs and intense competition, particularly in the low-margin EV segment. Despite these pressures, the company expects the two-wheeler industry to grow in high single digits in FY27, with Hero MotoCorp aiming to outperform through new launches across segments.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,
June 1, 2026